AbbVie

News

ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calqu...

AstraZeneca has thrown down the gauntlet to AbbVie and Johnson & Johnson with new data for Calquence in chronic lymphocytic leukaemia (CLL) that it says show a safety advantage over Imb

News

FDA clears Myovant's relugolix for uterine fibroids, setting...

Myovant has chalked up a second approval for its flagship drug relugolix from the FDA, becoming the first once-daily oral drug in the US to treat heavy menstrual bleeding associated with ut

News

Alvotech files lawsuit challenging AbbVie's Humira patent th...

Biosimilars firm Alvotech has filed a lawsuit that challenges AbbVie’s legal defences surrounding the inflammatory disease drug Humira in the US.

News

FDA holds back from action over Xeljanz safety study

The FDA has said it will wait for additional results from last week’s trial showing an increased risk of cardiac side effects with Pfizer’s arthritis blockbuster Xeljanz before deciding on

News

Bad news for Pfizer as blockbuster Xeljanz flunks safety stu...

JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and cancers added to its label in 2019.

News

AZ says Calquence is a safer drug than Imbruvica

AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment of chronic lymphocytic leukaemia (CLL).

ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calqu...

FDA clears Myovant's relugolix for uterine fibroids, setting...

Alvotech files lawsuit challenging AbbVie's Humira patent th...

FDA holds back from action over Xeljanz safety study

Bad news for Pfizer as blockbuster Xeljanz flunks safety stu...

AZ says Calquence is a safer drug than Imbruvica

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks